Benchmark International Logo Blog Mergers and Acquisitions

Archives

Benchmark International Successfully Facilitated the Acquisition of Comprehensive Clinical Trials and Advanced Clinical Trials by Vitalink Research

Benchmark International has successfully facilitated the acquisition of Comprehensive Clinical Trials, LLC and Advanced Clinical Trials, LLC (hereinafter referred to as CCT) by Vitalink Research, LLC. (hereinafter referred to as Vitalink).

CCT is an accomplished clinical research site specializing in conducting Phase II - IV clinical trials. It serves over 400 sponsors ranging from small biotech companies to the world's largest pharmaceutical and medical device companies and has completed hundreds of trials.

Vitalink is a US network of fully integrated clinical trial sites, connects world-class physicians and medical professionals with site managers and research coordinators to set the standard for the timely execution of clinical trial protocols with trustworthy results across all sites.

 

Ready to explore your exit and growth options?

 

I am excited to partner with the entire VitaLink Research team to further grow our combined business over the coming years,” said Dr. Ronald Ackerman, Founder and Medical Director of CCT. From my first meeting with VitaLink, it was clear that we shared a common culture rooted in clinical excellence and quality patient care. I look forward to this next chapter for myself and my dedicated staff”

“The partnership with Comprehensive Clinical Trials enables VitaLink to further establish itself as one of the leading wholly- owned clinical research site companies in the Southeast,” said Nick Wright, CEO of VitaLink Research. The addition of CCT partners VLR with the fantastic team that Dr. Ronald Ackerman has built throughout his distinguished career as a physician and Principal Investigator. This partnership expands our therapeutic capabilities into a very important and growing area of drug development research and our geographic footprint.

“I’m very excited for both CCT and VitaLink for consummating this partnership. As with every deal, this transaction faced a small number of issues through the diligence process. Thankfully, both sides had practiced professionals which allowed us to work through the various issues and find a way to make both sides happy. With this acquisition, VitaLink will break into theWomen’s Health sector with a major statement. Through the leadership of Dr. Ackerman, Vitalink will quickly become a widely recognized leader in this highly specialized study area.” said Benchmark International Associate Transaction Director David Steverson.

READ MORE >>

Pharma companies set for another big year for M&A

Political and economic uncertainty caused pharma M&A to slacken off in 2016, seeing deal values in the sector falling to $273.7bn from $392.4bn the previous year. While 2016 was far from catastrophic for pharma M&A it failed to reach the all-time highs achieved from the mega-deals in 2015, and the collapse of the $160bn mega-deal between Pfizer and Allergan was just one of the year’s setbacks for the sector.

READ MORE >>
1

    Subscribe to Email Updates

    Recent Posts

    Follow Us on Twitter

    Archive

    see all